MEMORANDUM OF UNDERSTANDING

Between

Signatures and Authentication for Everyone (SAFE)-BioPharma Association

and

The Kantara Initiative

I. Purpose

The purpose of this Memorandum is to define a mutually-beneficial, collaborative relationship between the SAFE-BioPharma Association and the Kantara Initiative. The parties wish to work together to advance the state of the art for enabling secure, trusted, privacy-enhancing, and interoperable online transactions among individuals, devices, businesses, and governments. To the extent that this goal helps to further the goals of cybersecurity globally, the parties agree to extend their work together in this area as well.

II. Background

SAFE-BioPharma is a non-profit association that created and manages digital identity and signature standards for the pharmaceutical and healthcare industries to promote interoperability and integration among researchers, vendors, regulators, clinicians, and other clinical research, pharmaceutical and healthcare stakeholders by providing a secure, enforceable and regulatory-compliant way to verify identities of parties involved in business-to-business and business-to-regulator electronic transactions.

Kantara Initiative is a global, open, and transparent community of identity, developer, and policy experts with stakeholders representing enterprise deployers, mobile operators, web 2.0 service providers, eGovernment agencies, IT vendors, and consumer electronics vendors. These individuals and organizations are have come together in Kantara Initiative to collaboratively address the harmonization and interoperability challenges that exist between enterprise identity systems, Web 2.0 applications and services, and Web-based initiatives.

III. Collaboration

The parties agree that to further their common goal of collaboration, designated representatives of each shall be welcome to join in and participate in the work groups and activities of the other as they relate to advancing the goals expressed above. Each party has the right to identify work groups and activities in which participation by the other’s
representatives is felt to be inappropriate and therefore disallowed. No funds shall be exchanged to enable this collaborative relationship.

IV. Contacts

Unless otherwise specified, the designated representatives of each party will serve as points of contact. If another individual is to be designated as point of contact, his or her name shall be transmitted to the other point of contact by the designated representative named below.

V. Duration, Modification and Termination

This MOU shall become effective on the latest date of the Parties’ signatures below and shall remaining effect for a period of one (1) year unless modified in writing by the mutual agreement of the parties, and shall be renewed automatically for a period of four years unless terminated in writing by one of the parties. Any party wishing to terminate its participation in this MOU may do so by giving thirty (30) days written or electronic notice to the other Parties.

By the signatures below of their duly authorized representatives, each Party agrees to the terms of this MOU:

For SAFE-BioPharma:

For Kantara Initiative:

Date: April 15, 2014

Joan Brennan

Digitally signed by Mollie Shields Lobing
DN: c=US, o=SAFE BIOPHARMA,
gu=29fe3698-d872-48f1-65a5-10e6b970c7e2, cn=Mollie Shield Lobing
Reason: I agree to the terms defined by the placement of my signature on this document
Date: 2014.04.16 15:54:44 -04'00"